NEWS
ADOCIA
“Innovative medicine for everyone, everywhere”
Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.
Adocia is specialized in insulin therapy and the treatment of the diabetic foot one of the main complications of diabetes Adocia. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets for which ADOCIA is developing new products represent more than USD 20 billion (USD 17 billion for insulin therapy and USD 3 billion for diabetic foot ulcer healing).
Through its BioChaperone® state-of-the-art technological platform, Adocia enhances the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.
Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer healing product. Adocia also confirmed the value of its technology for the formulation of a fast-acting insulin analog by signing an exclusive worldwide license agreement with a major pharmaceutical company. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.
To be a global leader for the formulation of therapeutic proteins
Based on its experience and recognised know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.
Adocia’s therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterised in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.
Adocia is listed on the regulated market of NYSE Euronext in Paris (ISIN : FR0011184241, mnemo / Reuters / Bloomberg : ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech Index.
News
> 12-06-13: Strengthening intellectual property on Adocia’s lead project for its chronic wounds treatment
> 12/04/23: Positive phase II clinical results for the treatment of diabetic foot ulcer
> 12/03/15: Adocia increases the size of its IPO to €27.4 million
Download
> 12/02/29 : Strong growth in operating income in 2011
Download
> 12/02/28: Positive phase IIa clinical results on its fast-acting human insulin, HinsBet®
Download
> 12/02/14: First IPO of the year on the NYSE Euronext Paris regulated market
Contact
Adocia
115 avenue Lacassagne
69003 Lyon
Tél : +33 (0)4 72 610 610
contactinvestisseurs@adocia.com
www.adocia.com
